Important Updates on COVID-19

As the COVID-19 (coronavirus) pandemic continues to evolve around the world, Otsuka stands united with our global community to navigate this fast moving and complex healthcare event.

Read the full statement

Otsuka Pharmaceutical Development & Commercialization, Inc. Launches NephU, an Online Healthcare Community Dedicated to Kidney Health

July 8, 2020 – Princeton, N.J. – Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announces the launch of NephU ( (formerly PKDnetwork), a community and online resource library designed for healthcare professionals working in nephrology (study of the kidney) to help engage, collaborate, and share resources for people living with kidney disease. NephU offers its members access to a growing on-demand library of educational materials, tools, including disease simulators, and resources curated for the healthcare community caring for patients with kidney disease. Through a variety of formats including video, audio, webinars, podcasts and social media, NephU members gain insights from nephrology thought leaders, a team of community advisors with expertise in kidney disease. “We are excited to launch NephU as a value-added resource to the nephrology community. We plan to offer a wide range of information and resources in areas such as polycystic kidney disease (PKD) and other hereditary kidney diseases, general chronic kidney disease, anemia associated with Chronic Kidney Disease (CKD), renal replacement therapy options, and behavioral health for people living with kidney conditions,” said Reza Moghadam, PharmD, MBA, senior director, Field Medical Affairs, OPDC. “Our goal is to expand and excite the conversation regarding best practices for kidney care and health. In the future, we plan to offer a microsite where patients and caregivers can directly access content.” For more information or to join NephU, visit About Otsuka Pharmaceutical Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy, "Otsuka–people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated to clinical development of promising drug candidates and services in mental health, oncology, cardio-renal, nephrology and digital health. Other activities include strategic planning for drug approval, marketing, and lifecycle management to maximize a product's full potential. OPDC is an indirect subsidiary of Otsuka Pharmaceutical Company, Ltd., which is part of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019.  All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at Contact for media Otsuka In U.S.                                                                                             Robert Murphy
Corporate Communications
Otsuka America Pharmaceutical, Inc.
+1 609 249 7262